News

Trevyent is SteadyMed’s lead drug product candidate currently under development stage that combines its PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat PAH. As part of

The deal will see the firms use T cell therapeutic strategies to develop treatments for these patients with an initial focus on Chimeric Antigen Receptor Technology (CAR-T) and

Currently, Tivorbex capsules are now available by prescription at pharmacies across the country. Tivorbex 20mg and 40mg dosage strengths are 20% lower than the 25mg and 50mg indomethacin

TriCalm Hydrogel was the company’s initial product in itch-relief product line and these two new products strategically expand the brand’s line of steroid-free, anti-itch products to further benefit

Spinifex is focused on developing a peripheral approach to treat neuropathic pain such as EMA401, a new angiotensin II Type 2 receptor (AT2R) antagonist. EMA401 is being developed

In the CF lung, the epithelial sodium channels (ENaC) hyperabsorb sodium and water from the surface of the lung airway, this leads to dehydration of the mucus layers

QR-010, a RNA-based oligonucleotide, is designed to address the underlying cause of the disease by repairing the mRNA defect encoded by the DF508 mutation in the CFTR gene

In the last three years, Pro Bono Bio has successfully launched and grown Flexiseq and Flexiseq Sport across the UK and other global markets including Europe, Asia and

With access to these funds, WCCT Global is pursuing both strategic organic expansion and new research capabilities within Asia and Europe, with the intent of improving their early